Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

How Lifecycle Maintenance Failures Affect Validated CSV Systems in Pharma

During a project, Zamann supported a German pharmaceutical company to strengthen CSV compliance with EMA and FDA expectations. However, the team identified a common and risky assumption. The company believed that a system remains valid because it was validated years ago.

This approach does not meet regulatory expectations. FDA, EMA, and GAMP5 clearly require continuous assessment, monitoring, and requalification of validated systems. Therefore, companies must actively maintain the validated state over time. In addition, validation cannot remain a one-time activity linked only to PQ execution.

As a result, the system must stay in a validated state every day. Not only at the moment of qualification, but throughout its entire lifecycle.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • No periodic review process: The company did not implement structured periodic reviews. As a result, the team did not reassess the validated state, and lifecycle verification was missing.
  • Vendor updates not assessed: The company deployed vendor updates without prior assessment. Consequently, their impact on the validated system was not evaluated, and changes lacked documented justification.
  • No trending of performance metrics: The team did not trend performance metrics over time. Therefore, they could not detect gradual performance drift or changes in system behavior.
  • Change control lacked impact assessment: Change control activities excluded impact assessment. As a result, the team did not evaluate effects on the validated state, and compliance was not supported.
  • No requalification strategy: The company did not define a requalification strategy. Therefore, no criteria existed to reassess the system, and validation status remained unverified.

Zamann Pharma Support’s Approach

 

  • Detailed Assessment: Zamann Pharma Support reviewed IQ, OQ, and PQ executions in detail. It also checked periodic requalification history and maintenance records. However, no formal reassessment of validated state occurred over a three-year period.
  • Lifecycle Gap Identification: The review identified missing preventive maintenance and lack of structured trending for critical parameters. Annual validated state confirmation was not documented. In addition, vendor updates and system changes were not formally assessed.
  • Requalification and Periodic Review Structuring: The team defined a clear periodic review structure with fixed reassessment intervals. They also established trending frequency and validated state confirmation criteria. Standard documentation templates were prepared to support consistency.
  • Preventive Maintenance and Trending Integration: Maintenance shifted from reactive to preventive scheduling. Critical parameters such as TOC, CFU, temperature, and pressure were included in structured trending. This improved early detection of system drift.
  • Governance Alignment: Validated state responsibilities were integrated into the QMS. Annual reassessment ownership was assigned clearly. Lifecycle indicators were also embedded into quality oversight processes.

Results Achieved

  • Structured Periodic Reassessment Implemented: A structured periodic review cycle is implemented across defined intervals. As a result, systems are continuously evaluated, and ongoing compliance is maintained.
  • Preventive Maintenance Strategy Established: A preventive maintenance strategy replaces reactive practices. Consequently, equipment reliability has improved, and potential failures are addressed before impacting performance or validation.
  • Formalized Historical Performance Trending: Historical performance trending is formalized across key parameters such as TOC, CFU, temperature, and pressure. Moreover, this enables early deviation detection and supports data-driven control.
  • Annual Validated State Review Embedded: An annual validated state review is embedded into governance. Therefore, system qualification remains under continuous oversight and aligned with regulatory expectations.
  • Improved System Predictability: System predictability has improved through continuous monitoring and structured evaluation. As a result, system behavior is more stable, and lifecycle validation remains controlled.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. How is a validated system interpreted during inspection when it has no documented periodic review despite years of production use?

In inspection terms, the system is not considered to have a confirmed continued validated state. Initial validation only demonstrates fitness at release, not sustained compliance over time. When periodic review is missing, there is no documented mechanism to verify that system performance, configuration stability, and operational behavior remain aligned with validated conditions throughout its lifecycle.

2. What is the compliance impact when vendor updates are installed on a validated system without formal impact assessment in a CSV-controlled environment?

This is treated as an uncontrolled change to a validated system. Even if functionality appears unaffected, the absence of documented impact assessment breaks the link between change control and validation assurance. As a result, the system configuration cannot be considered controlled under lifecycle validation principles, because post-change equivalence to the validated state is not demonstrated.

Because absence of failures does not equal proof of stability. Without structured trending of system performance, there is no evidence that gradual drift, degradation, or hidden variability has been evaluated over time. Therefore, the validated state cannot be continuously justified, since lifecycle assurance depends on observable system behavior trends rather than isolated compliant outputs.